PITTSBURGH--(BUSINESS WIRE)--Cellumen, a discovery toxicology company, today announced a new Cellular Systems Biology (CSB) panel to predict cardiac hypertrophy earlier in the drug discovery and development process. By integrating this new panel into Cellumen’s CellCiphr Discovery Toxicology profiling services, drug companies can now save millions of dollars in development costs that are typically wasted by not identifying toxic compounds earlier.